Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off “Join the Pace Makers,” a national campaign designed to empower people with a condition called bradycardia, also known as a slow heartbeat, to learn about their available treatment options so that they can have an informed conversation with their doctor.
People living with bradycardia can experience a number of symptoms ranging from general lethargy and shortness of breath to fainting or syncope. There are a number of treatment options available, including medication therapy and implanting a pacemaker, which delivers electrical pulses to help regulate a person’s heartbeat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52990-debbie-allen-and-medtronic-join-the-pace-makers
On October 21st, 2011, Lancôme invites customers to experience the “Beauty of Giving” by celebrating Genes Day, a one-day national event Lancôme began in 2010 to support St. Jude Children’s Research Hospital, one of the world’s premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases. On this day, Lancôme will donate $7 from the sale of every bottle of Génifique Youth Activating Concentrate to St. Jude. (This is in addition to special promotions and events nationwide surrounding Genes Day throughout the month of October.)
To view Multimedia News Release, go to http://www.multivu.com/mnr/52300-lancome-genes-day-2011-st-jude-julia-roberts-genifique-beauty-of-giving
The Sanford Guide, recognized as the essential reference for infectious disease treatment, announced the release of its first mobile app for the iPhone, iPod touch and iPad. The Sanford Guide App, available on Apple’s App Store for $29.99, contains the comprehensive guidelines and recommendations featured in the well-known pocket-size guides used by health care professionals in treatment decision making for over 40 years.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sanfordguide/50808/
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
“Explore Your Treatment Options,” a new multimedia ad campaign announced today by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ) and the Ad Council, encourages patients to become more informed about their options before choosing a treatment for a health condition or illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50583/
Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
As many as one in five U.S. teens suffers from disabling mental illness. Throughout Mental Health Awareness Month in May, BeSmartBeWell.com highlights the issue of mental illness in teens and tells the stories of two teens who moved from diagnosis through treatment and recovery.
What does mental illness look like in teens? It looks like Colleen, who’s battled depression and anxiety since she was 13, and Katie, who struggled with addiction in her early teens. Mental illness in teens looks just like the kid next door – studies show nearly half of all youth will experience a mental disorder at some point in their lives.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/besmartbewell/50033/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
The American Pain Foundation (APF) announced today the launch of new information and resources on pain medication safety for acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) as a part of its PainSAFE™ educational initiative. The new information will be launched with a national public service announcement (PSA) emphasizing the safe use of pain treatment options, particularly medications containing NSAIDs (aspirin, ibuprofen, naproxen) and acetaminophen (Tylenol, APAP). APF is the nation’s largest consumer advocacy organization dedicated to people with pain.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/painfoundation/49865/
